<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429764</article-id><article-id pub-id-type="pmcid-ver">PMC12429764.1</article-id><article-id pub-id-type="pmcaid">12429764</article-id><article-id pub-id-type="pmcaiid">12429764</article-id><article-id pub-id-type="doi">10.3390/ijms26178646</article-id><article-id pub-id-type="publisher-id">ijms-26-08646</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cells Derived from Concentrated Growth Factor Exhibit a Multilineage Differentiation Capacity</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9597-3862</contrib-id><name name-style="western"><surname>Giannotti</surname><given-names initials="L">Laura</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-ijms-26-08646" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0726-2081</contrib-id><name name-style="western"><surname>Calabriso</surname><given-names initials="N">Nadia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-ijms-26-08646" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5274-3939</contrib-id><name name-style="western"><surname>Spedicato</surname><given-names initials="F">Francesco</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af3-ijms-26-08646" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3288-490X</contrib-id><name name-style="western"><surname>Palermo</surname><given-names initials="A">Andrea</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-ijms-26-08646" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3073-9338</contrib-id><name name-style="western"><surname>Di Chiara Stanca</surname><given-names initials="B">Benedetta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-ijms-26-08646" ref-type="aff">1</xref><xref rid="af4-ijms-26-08646" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1145-6674</contrib-id><name name-style="western"><surname>Demitri</surname><given-names initials="C">Christian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-ijms-26-08646" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>De Sangro</surname><given-names initials="MA">Maria Antonietta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af5-ijms-26-08646" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carluccio</surname><given-names initials="MA">Maria Annunziata</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-ijms-26-08646" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7828-9519</contrib-id><name name-style="western"><surname>Damiano</surname><given-names initials="F">Fabrizio</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-ijms-26-08646" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6890-3674</contrib-id><name name-style="western"><surname>Siculella</surname><given-names initials="L">Luisa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-ijms-26-08646" ref-type="aff">1</xref><xref rid="c1-ijms-26-08646" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0087-1231</contrib-id><name name-style="western"><surname>Stanca</surname><given-names initials="E">Eleonora</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-ijms-26-08646" ref-type="aff">1</xref><xref rid="c1-ijms-26-08646" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Fierro</surname><given-names initials="FA">Fernando A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-26-08646"><label>1</label>Department of Experimental Medicine (DiMeS), University of Salento, 73100 Lecce, Italy; <email>laura.giannotti@unisalento.it</email> (L.G.); <email>andrea.palermo@unisalento.it</email> (A.P.); <email>benedetta.dichiara@unisalento.it</email> (B.D.C.S.); <email>christian.demitri@unisalento.it</email> (C.D.); <email>fabrizio.damiano@unisalento.it</email> (F.D.)</aff><aff id="af2-ijms-26-08646"><label>2</label>Institute of Clinical Physiology (IFC), National Research Council (CNR), 73100 Lecce, Italy; <email>nadia.calabriso@cnr.it</email> (N.C.); <email>mariaannunziata.carluccio@cnr.it</email> (M.A.C.)</aff><aff id="af3-ijms-26-08646"><label>3</label>Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, 73100 Lecce, Italy; <email>francesco.spedicato@unisalento.it</email></aff><aff id="af4-ijms-26-08646"><label>4</label>Institute of Polymers, Composites and Biomaterials, National Research Council (IPCB-CNR), 80125 Naples, Italy</aff><aff id="af5-ijms-26-08646"><label>5</label>Blood Trasfusion Center, Vito Fazzi Hospital, 73100 Lecce, Italy; <email>madesangro@gmail.com</email></aff><author-notes><corresp id="c1-ijms-26-08646"><label>*</label>Correspondence: <email>luisa.siculella@unisalento.it</email> (L.S.); <email>eleonora.stanca@unisalento.it</email> (E.S.)</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>26</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496188</issue-id><elocation-id>8646</elocation-id><history><date date-type="received"><day>24</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>18</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-26-08646.pdf"/><abstract><p>Concentrated growth factor (CGF) is an autologous blood-derived product widely used in regenerative medicine due to its high concentration of growth factors and platelets. In this study, the ability of primary stem cells isolated from human CGF to differentiate into adipocytes, endothelial cells, and neuronal-like cells was evaluated in vitro. CGF primary cells (CPCs) were obtained from CGF fragments and characterized after one month in culture. These cells were positive for the surface markers CD105, CD45, CD31, and CD14, and also expressed mRNA levels of the stemness markers Nanog and Oct3/4 comparable to human bone marrow mesenchymal stem cells (BMSCs). Results showed that, following appropriate differentiation protocols, CPCs, similarly to BMSCs, were able to differentiate into adipogenic, endothelial, and neuronal lineages, acquiring specific phenotypic and molecular markers. Adipogenic induction resulted in lipid accumulation and the upregulation of key genes, including PLIN2, FABP4, CD36, and FASN. Under pro-endothelial conditions, the cells exhibited increased expression of endothelial markers, eNOS, VEGFR-2, and CD31. Neuronal induction promoted the expression of &#946;-tubulin III, Nestin, and Neurofilament. Overall, this work highlights the remarkable plasticity of CPCs and supports their potential application in multilineage regenerative therapies.</p></abstract><kwd-group><kwd>concentrated growth factors</kwd><kwd>stem cells</kwd><kwd>cell differentiation</kwd><kwd>circulating stem cells</kwd><kwd>regenerative medicine</kwd><kwd>tissue regeneration</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-26-08646"><title>1. Introduction</title><p>The use of autologous platelet concentrates (APCs) in regenerative medicine has been steadily increasing due to their ability to promote wound healing and tissue regeneration [<xref rid="B1-ijms-26-08646" ref-type="bibr">1</xref>]. Certain blood components, such as peripheral blood mononuclear cells, may contain a small fraction of circulating stem cells or multipotent progenitor cells involved in the inflammatory response and in the tissue repair process following injury [<xref rid="B2-ijms-26-08646" ref-type="bibr">2</xref>,<xref rid="B3-ijms-26-08646" ref-type="bibr">3</xref>,<xref rid="B4-ijms-26-08646" ref-type="bibr">4</xref>]. Under specific microenvironmental conditions, monocytes can also exhibit pluripotent features and the ability to differentiate into various cell types, including epithelial, endothelial, neuronal cells, and hepatocytes [<xref rid="B4-ijms-26-08646" ref-type="bibr">4</xref>,<xref rid="B5-ijms-26-08646" ref-type="bibr">5</xref>]. The cell populations isolated from APCs, including monocytes, provide a valuable resource for studying cellular responses in regenerative contexts. These cells have demonstrated potential differentiation capabilities into multiple lineages, although they express distinct markers compared with mesenchymal stromal cells typically used in medical applications [<xref rid="B6-ijms-26-08646" ref-type="bibr">6</xref>].</p><p>APCs are enriched in cytokines, growth factors, and extracellular matrix proteins that play crucial roles in cell proliferation, migration, and differentiation. Recent advances in the preparation and clinical application of platelet derivatives have further expanded their therapeutic potential. Studies have shown that the application of APCs can significantly improve healing outcomes in pathological conditions such as diabetes, alopecia, or nerve injuries [<xref rid="B7-ijms-26-08646" ref-type="bibr">7</xref>,<xref rid="B8-ijms-26-08646" ref-type="bibr">8</xref>,<xref rid="B9-ijms-26-08646" ref-type="bibr">9</xref>,<xref rid="B10-ijms-26-08646" ref-type="bibr">10</xref>].</p><p>Concentrated growth factor (CGF), a third-generation of APC, contains high levels of growth factors, leukocytes, and a heterogeneous population of cells expressing surface markers typical of hematopoietic stem cells and mesenchymal stromal cells, including endothelial progenitor cells [<xref rid="B11-ijms-26-08646" ref-type="bibr">11</xref>,<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>]. Owing to their ability to support the recruitment, proliferation, and maturation of cells involved in tissue regeneration, platelet concentrates are particularly beneficial for poorly vascularized tissues with slow cell turnover and limited extracellular matrix repair capacity [<xref rid="B14-ijms-26-08646" ref-type="bibr">14</xref>].</p><p>Transforming growth factor &#946; (TGF-&#946;), bone morphogenetic proteins (BMPs), vascular endothelial growth factor (VEGF), and matrix metalloproteinases (MMPs), such as MMP-2 and MMP-9, are present at high concentrations in CGFs and are released gradually and sustainably over time. This property makes CGFs especially well-suited to supporting the later stages of regeneration, in contrast to other APCs that release their growth factors more rapidly [<xref rid="B15-ijms-26-08646" ref-type="bibr">15</xref>,<xref rid="B16-ijms-26-08646" ref-type="bibr">16</xref>].</p><p>We previously characterized CGF from both morphological and functional perspectives. One of the most important features of this biomaterial is the composition and properties of the cells entrapped within the fibrin matrix, as these cells actively contribute to its regenerative potential. Our previous findings described CGF as a heterogeneous structure: the outer portion consists of a dense, compact fibrin network, whereas the inner portion contains a rich, uniformly distributed cell population embedded within the three-dimensional fibrin matrix [<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>].</p><p>Gene expression analyses have demonstrated that cells isolated from CGF express pluripotency-associated genes such as Oct3/4 and Nanog. Oct3/4 plays a critical role in maintaining stem cell identity and is a key transcription factor in multipotent progenitors, whereas Nanog is essential for self-renewal in embryonic stem cells [<xref rid="B17-ijms-26-08646" ref-type="bibr">17</xref>]. These data highlight that CGF cells exhibit marked plasticity, as it has been previously demonstrated that they can differentiate into osteoblasts [<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>].</p><p>Furthermore, CGF has been shown to promote neuronal recovery and regenerative processes [<xref rid="B9-ijms-26-08646" ref-type="bibr">9</xref>,<xref rid="B10-ijms-26-08646" ref-type="bibr">10</xref>]. In particular, studies using CGF prepared from rat venous blood and applied to nerve injuries demonstrated enhanced Schwann cell migration and &#946;1 integrin activation, ultimately facilitating neuronal regeneration [<xref rid="B18-ijms-26-08646" ref-type="bibr">18</xref>]. Recent clinical studies have also shown that combining autologous CGF with adipose tissue grafts improves the survival of transplanted tissue when used to treat facial contour deformities [<xref rid="B19-ijms-26-08646" ref-type="bibr">19</xref>]. Additionally, in vitro experiments have revealed that CGF can stimulate the proliferation, migration, and angiogenic differentiation of human umbilical vein endothelial cells (HUVECs) [<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>], indicating its potential application in revascularization therapies [<xref rid="B20-ijms-26-08646" ref-type="bibr">20</xref>].</p><p>Although the osteogenic potential of these cells has been well characterized, their ability to differentiate into other lineages remains largely unexplored. Given the multipotent nature of the CGF cells, this study aims to investigate their in vitro behavior in order to assess their potential to differentiate into alternative phenotypes.</p><p>To this end, primary cells were isolated from CGF and cultured under different conditions using lineage-specific induction media to promote differentiation into three cell types of clinical and regenerative interest: adipocytes, endothelial cells, and neurons.</p><p>The objective of this study is therefore to further elucidate the plasticity of CGF primary cells (CPCs) by exploring their differentiation potential beyond osteogenesis, and to identify novel clinical applications in the field of tissue regeneration.</p></sec><sec sec-type="results" id="sec2-ijms-26-08646"><title>2. Results</title><sec id="sec2dot1-ijms-26-08646"><title>2.1. CPCs Express Stem Markers</title><p>After 15 days in culture medium, the CGF was cut into fragments and incubated in fresh medium. Cells released from the CGF fragments, after approximately one month in culture, showed morphologically heterogeneous (<xref rid="ijms-26-08646-f001" ref-type="fig">Figure 1</xref>A), including a high percentage of elongated cells that increased over time (21 days). To characterize these cells, we performed quantitative real-time PCR to analyze the expression of mesenchymal stromal cell and hematopoietic stem cell markers, as well as stemness markers, and compared them with those commonly expressed by human bone marrow mesenchymal stem cells (BMSCs).</p><p>Quantitative analysis revealed that CPCs expressed levels of CD105 mRNA at levels comparable to BMSCs. However, unlike BMSCs, CPCs did not express typical mesenchymal stem cell markers such as CD90 and CD73 (<xref rid="ijms-26-08646-f001" ref-type="fig">Figure 1</xref>B). Neither cell population, CPCs or BMSCs, expressed the hematopoietic stem cell marker CD34, but the CPCs displayed markedly higher CD45 mRNA levels compared to BMSCs, in which this marker is absent. Although to a lesser extent than BMSCs, CPCs showed detectable OCT3/4 and NANOG mRNA, two transcription factors crucial for maintaining pluripotency.</p><p>Furthermore, CPCs showed CD14 and CD36 mRNA levels approximately 26-fold and 25-fold higher, respectively, than those observed in BMSCs, and exhibited high levels of CD31 mRNA.</p></sec><sec id="sec2dot2-ijms-26-08646"><title>2.2. CPCs Differentiate into Adipocytes </title><p>To evaluate adipogenic differentiation, lipid droplet formation was analyzed by Oil Red O (ORO) staining after 14 days of adipogenic induction. ORO staining revealed a significant increase in lipid droplet formation in treated CPCs compared with controls. Moreover, CPCs cultured in adipogenic medium changed morphology from spindle-shaped to spherical (<xref rid="ijms-26-08646-f002" ref-type="fig">Figure 2</xref>A). The measurements of absorbance of ORO staining confirmed a marked increase in intracellular lipid accumulation in adipogenic medium-treated cells as compared with controls (<xref rid="ijms-26-08646-f002" ref-type="fig">Figure 2</xref>B).</p><p>Principal component analysis (PCA) summarized the main variations in the dataset. CPCs treated with the adipogenic medium clustered separately from controls, suggesting that the treatment induced consistent and specific changes, most likely related to the adipogenic differentiation process (<xref rid="ijms-26-08646-f002" ref-type="fig">Figure 2</xref>C).</p><p>Morphometric analysis showed that treated cells had a significantly higher roundness value, reflecting a more spherical shape, and a reduced perimeter-to-area ratio, consistent with a more compact and regular morphology (<xref rid="ijms-26-08646-f002" ref-type="fig">Figure 2</xref>C).</p><p>Furthermore, CPCs reduced the expression of CD45 and CD105 surface markers after adipogenic differentiation compared to control cells (<xref rid="ijms-26-08646-f002" ref-type="fig">Figure 2</xref>D).</p><p>At 7 and 14 days post-induction, quantitative real-time PCR confirmed time-dependent increases in adipogenic markers. PLIN2 and FABP4 mRNA levels increased progressively, while FASN and CD36 mRNA levels were significantly upregulated at 14 days but not at 7 days compared to undifferentiated cells (<xref rid="ijms-26-08646-f002" ref-type="fig">Figure 2</xref>D). Western blot analysis showed that undifferentiated CPCs weakly expressed PPAR&#947;, adiponectin, and FASN proteins; however, their expression strongly increased after the adipogenic treatment (<xref rid="ijms-26-08646-f002" ref-type="fig">Figure 2</xref>E).</p><p>A commonly used cell line, valued for its plasticity and differentiation capacity, is represented by BMSCs. The ORO staining revealed strong lipid accumulation in BMSCs treated with adipogenic medium for 14 days, whereas control cells showed no staining. Morphological analysis confirmed these changes (<xref rid="ijms-26-08646-f003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="sec2dot3-ijms-26-08646"><title>2.3. CPCs Differentiate into Endothelial Cells</title><p>To assess endothelial differentiation, CPCs were cultured in endothelial induction medium for 14 days, and marker expression was analyzed by immunocytochemistry and real-time PCR. Endothelial nitric oxide synthase (eNOS) and vascular endothelial growth receptor-2 (VEGFR-2) were detected by immunostaining, supporting endothelial commitment (<xref rid="ijms-26-08646-f004" ref-type="fig">Figure 4</xref>A). Real-time PCR confirmed increased expression of eNOS and VEGFR-2 compared with controls. CD31, another marker of endothelial cells, showed mRNA levels higher in differentiated cells than in control cells (<xref rid="ijms-26-08646-f004" ref-type="fig">Figure 4</xref>B). The expression of hematopoietic, CD45, and mesenchymal markers, CD105, was also evaluated. CD45 mRNA expression was significantly reduced, while CD105 mRNA did not show a reduction in treated cells with respect to control cells (<xref rid="ijms-26-08646-f004" ref-type="fig">Figure 4</xref>C).</p><p>BMSCs were treated for 7 and 14 days with the same endothelial differentiation medium used for CPCs. Immunostaining revealed high eNOS expression as early as 6 days. The staining intensity, directly proportional to the protein expression levels, was greater after 14 days. The expression of VEGFR-2 is less pronounced compared to eNOS; however, a positive signal becomes evident after 14 days of treatment with respect to undifferentiated BMSC (<xref rid="ijms-26-08646-f005" ref-type="fig">Figure 5</xref>A). This finding is comparable to that observed in CGF-related cells (<xref rid="ijms-26-08646-f004" ref-type="fig">Figure 4</xref>A). BMSCs treated with VEGF for 7 and 14 days showed mRNA of endothelial markers such as CD105, CD31, eNOS, and VEGFR-2 upregulated with respect to CTR, especially at the end of differentiation time (<xref rid="ijms-26-08646-f005" ref-type="fig">Figure 5</xref>B).</p></sec><sec id="sec2dot4-ijms-26-08646"><title>2.4. Differentiation of CPCs into Neuron-like Cells</title><p>To evaluate the ability of CPCs to acquire a neuron-like phenotype, cells were cultured in neuronal induction medium and analyzed by immunocytochemistry, molecular, and protein analyses.</p><p>As illustrated in <xref rid="ijms-26-08646-f006" ref-type="fig">Figure 6</xref>A, &#946;-Tubulin III (TUBB3) immunohistochemical staining revealed a positive signal in cells treated with the neuronal differentiation medium (Neu), contrasting with the untreated control (CTR). The cells in Neu condition displayed a more extended morphology with thin, elongated cytoplasmic processes consistent with a neuronal-like phenotype. This is supported by the morphological analysis (<xref rid="ijms-26-08646-f006" ref-type="fig">Figure 6</xref>B), which showed an increased perimeter-to-area ratio in the Neu condition, indicating that the cells exhibited a more complex, branched morphology. The significant reduction in solidity in the Neu condition is consistent with enhanced neuronal differentiation, involving the extension of cellular processes and resulting in a less compact shape. Finally, the PCA demonstrates that the observed morphological features effectively discriminate between the two conditions (<xref rid="ijms-26-08646-f006" ref-type="fig">Figure 6</xref>B).</p><p>Real-time PCR showed reduced CD45 and CD105 expression in Neu cells (<xref rid="ijms-26-08646-f006" ref-type="fig">Figure 6</xref>C), while TUBB3, Nestin (Nes), and Neurofilament (NFL) were significantly upregulated. Western blot confirmed increased TUBB3 protein expression and reduced CD105 levels, consistent with a loss of mesenchymal features (<xref rid="ijms-26-08646-f006" ref-type="fig">Figure 6</xref>D).</p><p>In parallel with the experiments performed on primary cells released from CGF, a neuronal differentiation treatment was carried out on BMSCs to evaluate the efficiency of converting them to a neuronal fate. As illustrated in <xref rid="ijms-26-08646-f007" ref-type="fig">Figure 7</xref>A, immunocytochemistry for TUBB3 revealed a significant increase in immunoreactivity in cells Neu, contrasting with CTR, which retained a fibroblast-like morphology and exhibited minimal expression of the TUBB3 marker. The morphological change, confirmed by qualitative analysis, is illustrated in the graphs showing the analysis of the perimeter/area ratio, solidity, and PCA (<xref rid="ijms-26-08646-f007" ref-type="fig">Figure 7</xref>B).</p><p>The morphological observations were corroborated by gene expression analysis using real-time PCR. <xref rid="ijms-26-08646-f007" ref-type="fig">Figure 7</xref>C illustrates a significant decrease in the mesenchymal markers CD105 and CD45 mRNA abundance in the treated cells compared to the control cells, indicating a loss of the original mesenchymal phenotype. Conversely, a significant upregulation of genes typically associated with the neuronal phenotype, such as Tubb3, Nestin, and NFL, was detected (<xref rid="ijms-26-08646-f007" ref-type="fig">Figure 7</xref>C), confirming the acquisition of a neuronal identity at the transcriptional level.</p><p>Protein expression analysis by Western blot confirmed these findings. As illustrated in <xref rid="ijms-26-08646-f007" ref-type="fig">Figure 7</xref>D,E, the treated cells exhibited a significant increase in TUBB3 protein level, consistent with the transcriptional data, and a notable decrease in CD105 protein level. &#946;-actin expression remained constant across samples and was used as an internal loading control, supporting the conclusion that neuronal differentiation was efficiently induced.</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-26-08646"><title>3. Discussion</title><p>CGF has recently gained attention as a versatile tool in regenerative medicine, with applications extending beyond traditional wound healing to encompass aesthetic, reconstructive, and even oncological settings. Its growing interest is largely attributable to its potent regenerative properties and the broad clinical potential associated with its unique composition [<xref rid="B21-ijms-26-08646" ref-type="bibr">21</xref>].</p><p>Our study aimed to determine whether CGF can be considered a reservoir of autologous stem cells with plasticity comparable to BMSCs, and whether this characteristic, combined with its high content of growth factors, may explain its ability to accelerate the healing of wounds, including chronic lesions, more rapidly than other platelet derivatives [<xref rid="B8-ijms-26-08646" ref-type="bibr">8</xref>,<xref rid="B22-ijms-26-08646" ref-type="bibr">22</xref>].</p><p>In clinical practice, CGF has been shown to promote hair regrowth in androgenetic alopecia, where a single subcutaneous injection of CGF into alopecic areas sustained hair regrowth for up to six months post-application [<xref rid="B23-ijms-26-08646" ref-type="bibr">23</xref>]. Promising outcomes have also been reported in anti-aging therapies and plastic surgery, particularly in facial rejuvenation procedures [<xref rid="B24-ijms-26-08646" ref-type="bibr">24</xref>]. In reconstructive surgery, CGF has been applied to enhance the repair of both hard and soft tissues. A well-established application is in the dental field, particularly in oral and maxillofacial surgery, including the treatment of temporomandibular disorders [<xref rid="B25-ijms-26-08646" ref-type="bibr">25</xref>,<xref rid="B26-ijms-26-08646" ref-type="bibr">26</xref>]. A recent meta-analysis, which includes a randomized controlled trial, demonstrates that the coronally advanced flap combined with CGF significantly improves clinical outcomes such as root coverage and gingival thickness when compared to the conventional approach [<xref rid="B27-ijms-26-08646" ref-type="bibr">27</xref>]. The regenerative capabilities of CGF have also proven effective in managing post-operative complications associated with cosmetic procedures as well. Notably, CGF has been employed to reverse necrotic skin damage resulting from hyaluronic acid filler injections, a rare but severe complication [<xref rid="B28-ijms-26-08646" ref-type="bibr">28</xref>]. These therapeutic effects are largely attributed to the gradual release of multiple growth factors embedded in the CGF fibrin matrix. Our previous work demonstrated a programmed and sequential release profile: VEGF peaked at day 14, TGF-&#946;1 and BMP-2 reached maximal concentrations by day 21, and remained elevated until day 28. Moreover, CGF is a source of MMP-2 and MMP-9, matrix metalloproteinases involved in extracellular matrix remodeling and cell migration, which peak around day 7 [<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>]. This gradual release, supported by the dense fibrin network, ensures a more controlled and less inflammatory delivery of bioactive molecules.</p><p>Mechanistically, CGF has been shown to attract fibroblasts by activating the MEK/ERK signaling pathway, thereby promoting tissue regeneration [<xref rid="B29-ijms-26-08646" ref-type="bibr">29</xref>]. In addition, CGF enhances revascularization of the damaged area, contributing to more effective tissue recovery [<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>,<xref rid="B30-ijms-26-08646" ref-type="bibr">30</xref>].</p><p>We have previously demonstrated that the sustained release of growth factors by CGF is also attributable to the cells entrapped within the fibrin matrix [<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>]. These cells form a heterogeneous population and exhibit a mixed immunophenotypic profile. The cells within the fibrin clot and released in two weeks from CGF expressed CD34, CD45, and CD105, indicating the presence of a cellular pool comprising hematopoietic stem cells, lymphocytes, monocytes, and endothelial progenitor cells (EPCs) [<xref rid="B11-ijms-26-08646" ref-type="bibr">11</xref>,<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>]. The release of EPC-like cells from CGF was confirmed by the expression of CD34 and endothelial markers, including eNOS, VE-cadherin, VEGFR-2, and CD31. These EPC-like cells promote angiogenesis by producing angiogenic factors such as VEGF, TGF-&#946;1, MMP-2, and MMP-9, actively participating in neovascularization and tissue remodeling. They are also able to integrate into pre-existing endothelial tubules, contributing to vascular structure formation in vitro [<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>].</p><p>In the present study, we isolated the cells by cutting the CGF after 15 days of incubation in medium. The CGF pieces released heterogeneous cell populations with a higher percentage of elongated cells compared to those released from intact CGF during the first 15 days [<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>].</p><p>After one month of culture, CGF-derived cells no longer expressed the hematopoietic marker CD34, which was observed in CGF cells at shorter culture times [<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-08646" ref-type="bibr">13</xref>]. However, they expressed high levels of monocyte-associated markers such as CD31, CD36, CD14, and CD45. Circulating monocytes are known to exhibit considerable plasticity and differentiation capacity under specific growth factor conditions [<xref rid="B5-ijms-26-08646" ref-type="bibr">5</xref>,<xref rid="B31-ijms-26-08646" ref-type="bibr">31</xref>]. In our experimental conditions, the growth factor-rich environment provided by CGF may be responsible for maintaining the plasticity of these cells. Interestingly, CPCs also expressed stemness markers typically associated with mesenchymal stromal cells, including significant levels of CD105, Oct3/4, and Nanog, comparable to those observed in BMSCs, indicating that their differentiation potential was preserved after long-term in vitro expansion.</p><p>However, can these cells differentiate into various cell types in response to different microenvironments and thus actively contribute to the regeneration at the injury site? To address this question, we induced the differentiation of CPCs into adipocytes, endothelial cells, and neuron-like cells.</p><p>CPCs cultured in adipogenic medium expressed high mRNA and protein levels of adipocyte-specific markers such as FASN, PPAR&#947;, and CD36. A marked accumulation of intracellular lipid vesicles further confirmed the ability to acquire a functional adipocyte phenotype. Overall, these results clearly and effectively demonstrate that primary cells respond to adipogenic treatment by acquiring a phenotype consistent with that of adipocytes, both morphologically and biochemically. The combination of quantitative, morphological, and statistical analyses strengthens the evidence supporting the success of the differentiation process.</p><p>The CPCs treated with endothelial differentiation medium expressed endothelial cell markers such as eNOS and VEGFR-2, as revealed by immunocytochemistry and quantitative real-time PCR. In addition, at 14 days after endothelial induction, CPCs increased CD31 mRNA levels compared to undifferentiated cells. However, a downregulation of stemness marker CD45 mRNA was shown in endothelial differentiated cells, whereas they exhibited high levels of CD105, consistent with its known role in endothelial lineage commitment [<xref rid="B32-ijms-26-08646" ref-type="bibr">32</xref>].</p><p>The CPCs can differentiate into neuron-like cells following a multistep differentiation protocol. The field of neurology supports the use of autologous formulations with a high platelet content to promote neurogenesis and the recovery and regeneration of neuronal structures [<xref rid="B9-ijms-26-08646" ref-type="bibr">9</xref>,<xref rid="B10-ijms-26-08646" ref-type="bibr">10</xref>]. Yang et al. evaluated the efficacy and underlying mechanisms of CGF in promoting facial nerve regeneration. Their study resulted in accelerated axonal and myelin repair, as well as increased proliferation of Schwann cells. In vitro, CGF was found to promote the proliferation and migration of RSC96 cells, as well as to facilitate axonal outgrowth in NG108-15 cells [<xref rid="B33-ijms-26-08646" ref-type="bibr">33</xref>].</p><p>Our results suggest that, in the Neu condition, cells exhibit stronger TUBB3 expression and more complex morphologies. Morphometric metrics (perimeter/area and solidity) confirm a phenotype consistent with neuronal differentiation. PCA analysis further supports the notion that the two populations are phenotypically distinct. This suggests that the treatment induces consistent and reproducible changes in cell morphology, and the quantitative analysis showed the expression of neuronal markers. These findings support the neuroregenerative potential of CPCs.</p><p>In addition to adipogenic, endothelial, and neuronal differentiation, we have previously demonstrated that CPCs can differentiate into osteoblasts by progressively downregulating stemness markers and acquiring osteogenic-specific genes such as RUNX2 and osteocalcin under osteoinductive conditions [<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>]. Osteogenic differentiation was further enhanced by culturing on silicon-doped hydroxyapatite scaffolds [<xref rid="B34-ijms-26-08646" ref-type="bibr">34</xref>]. To support our results, multipotent stem cells capable of differentiating into five different cell lineages for regenerative medicine applications have been isolated from platelet derivatives [<xref rid="B6-ijms-26-08646" ref-type="bibr">6</xref>,<xref rid="B35-ijms-26-08646" ref-type="bibr">35</xref>]. Furthermore, monocytes exhibit features of adult stem cells capable of differentiating into mesenchymal lineages [<xref rid="B5-ijms-26-08646" ref-type="bibr">5</xref>], and the CPCs shared characteristics with monocytes.</p><p>Future investigations will aim to evaluate the chondrogenic potential of CPCs to provide a more comprehensive understanding of the multipotent characteristics and to expand their translational applications to cartilage repair and osteoarticular regenerative medicine.</p><p>A major limitation of this study is the restricted number of donors from whom the cells were isolated. All participants included in the study were healthy individuals, and in our analysis, we did not observe a significant impact of donor sex or age on CPCs&#8217; immunophenotype and differentiation potential. The donor&#8217;s physiological condition undoubtedly influences the ability of CGF to contain and release multipotent cells. However, further studies involving patients requiring CGF-based treatments are necessary to assess whether the content and differentiation potential of CPCs vary under pathological or clinically relevant conditions. Moreover, it is important to consider that the number of peripheral blood stem cells increases following tissue injury, as part of a systemic regenerative response triggered by inflammatory and chemotactic signals. This mobilization process facilitates the recruitment of progenitor cells to the damaged site to support tissue repair [<xref rid="B36-ijms-26-08646" ref-type="bibr">36</xref>].</p><p>In conclusion, this work demonstrates that CGF contains CPCs with stemness characteristics that can be expanded in vitro and differentiated into adipocytes, endothelial cells, and neuronal-like cells in response to appropriate differentiation stimuli. The differentiation capacity of CPCs is comparable to that of BMSCs, indicating that CGF serves as an autologous reservoir of multipotent cells while simultaneously acting as a source of bioactive molecules. These findings highlight the dual therapeutic role of CGF as both a delivery system for growth factors and a stem/progenitor cell niche, underscoring its potential for broad applications in regenerative medicine.</p></sec><sec id="sec4-ijms-26-08646"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-26-08646"><title>4.1. Collection of CGF</title><p>Venous blood (8 mL) from 5 healthy, non-smoking adult donors, two females and three males, aged between 27 and 50 years old, was collected and immediately centrifuged by a Medifuge device (Medifuge MF200; Silfradent srl, Forl&#236;, Italy), at 25 &#176;C, using a program with the following characteristics: 30 s acceleration, 2 min 2700 rpm, 4 min 2400 rpm, 4 min 2700 rpm, 3 min 3000 rpm, and 36 s deceleration and stop, to obtain CGF clot, as previously described [<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>]. Informed consent was obtained from the donors included in this study in accordance with the Declaration of Helsinki. For each set of experiments, CGFs were prepared from the same blood sample of a single donor.</p></sec><sec id="sec4dot2-ijms-26-08646"><title>4.2. Isolation and Culture of CGF Primary Cells</title><p>The CGF clots were washed twice in PBS and incubated in a sterile dish with 2 mL of DMEM low glucose at 37 &#176;C in a humidified atmosphere with 5% CO<sub>2</sub> for 14 days. After, that, to obtain CPCs, CGF was cut into eight pieces which were seeded onto 6 cm culture plates and incubated in DMEM low glucose complete, containing 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin, 100 &#956;g/mL streptomycin, and 2 ng/mL FGF-2 (SRP4037, Sigma-Aldrich Merk Life Science S.r.l., Milan, Italy). CPCs adhered to the culture plate and grew until they reached confluence. The medium was replaced weekly (50% volume). After two passages, primary cells were detached using 0.02% EDTA/0.25% trypsin solution and seeded at a density of 1.5 &#215; 10<sup>4</sup> cells/mL into a 24-well plate for differentiation.</p></sec><sec id="sec4dot3-ijms-26-08646"><title>4.3. BMSC Culture</title><p>The BMSCs (PCS-500-012, ATCC, Rockville, MD, USA) were cultured at 37 &#176;C in a humidified atmosphere containing 95% air and 5% CO<sub>2</sub>. The cells were cultured in low-glucose DMEM (L0101-500, Voden Medical Instruments, Casorezzo, Italy), supplemented with 10% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) FBS (S181H-500, Voden Medical Instruments), 1% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) penicillin&#8211;streptomycin solution (P4333, Sigma-Aldrich, Milan, Italy) and 2 mM L-glutamine (X0550-100, Voden Medical Instruments), and 2 ng/mL FGF-2. Cultures were reseeded at ~80% confluence, with seeding density adjusted to plate dimensions.</p></sec><sec id="sec4dot4-ijms-26-08646"><title>4.4. Adipogenic Differentiation</title><p>To induce adipogenic differentiation, CPCs or BMSCs were cultured in adipogenic medium (high-glucose DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin, 100 &#956;g/mL streptomycin, 0.5 mM IBMX (I7018), 1 &#956;M dexamethasone (D4902), 10 &#956;M insulin (I3536), and 200 &#956;M indomethacin (I7378); all from Sigma-Aldrich). Adipogenic differentiation was evaluated by determining the expression of genes involved in adipogenesis, such as PPAR&#947;, PLIN2, FAS, FABP4, CD36, and adiponectin. Lipid droplets were revealed by Oil Red O staining (O1391, Sigma-Aldrich).</p></sec><sec id="sec4dot5-ijms-26-08646"><title>4.5. Endothelial Differentiation</title><p>To induce endothelial differentiation, CPCs or BMSCs were cultured in M199 medium supplemented with 2% FBS, 2 mM glutamine, 100 U/mL penicillin, 100 &#956;g/mL streptomycin, and 50 ng/mL VEGF. Medium was replaced every three days. Endothelial differentiation was evaluated by determining the expression of endothelial markers like eNOS, VEGFR-2, and CD31.</p></sec><sec id="sec4dot6-ijms-26-08646"><title>4.6. Neuronal Differentiation</title><p>At confluence, CPCs and BMSCs cells were divided into two groups, named control (CTR) and neuronal (Neu). In the CTR group, cells were cultured in DMEM low glucose medium with 10% FBS and 2 ng/mL FGF-2. The Neu group followed an 18-day differentiation protocol with four different serum-free DMEM-based media:<list list-type="simple"><list-item><label>(1)</label><p>24 h supplemented with 2% B27 (17504-044, Gibco, Segrate, Italy), 250 &#181;M 3-isobutyl-1-methylxanthine (IBMX, 28822-58, Sigma-Aldrich, Merk Life Science S.r.l., Milan, Italy), and 10 ng/mL FGF-2.</p></list-item><list-item><label>(2)</label><p>3 days with only 2% B27 supplementation.</p></list-item><list-item><label>(3)</label><p>7 days with 1 &#181;M all-trans retinoic acid (sc-200898 Santa Cruz, Segrate, Italy).</p></list-item><list-item><label>(4)</label><p>7 days with 2% B27 supplement and 10 ng/mL human brain-derived neurotrophic factor (BDNF, B3795 Sigma-Aldrich).</p></list-item></list></p><p>After 18 days of treatment, the cells were used for subsequent experiments.</p></sec><sec id="sec4dot7-ijms-26-08646"><title>4.7. Oil Red O Staining</title><p>After adipogenic treatment, the CPCs and BMSCs were washed with PBS and incubated with 4% paraformaldehyde in PBS pH 7.4 for 15 min, at room temperature. Then the cells were stained with 5% Oil Red O solution for 30 min in the dark at 37 &#176;C; they were washed three times with PBS, and the lipid droplets were observed and photographed at an inverted microscope.</p></sec><sec id="sec4dot8-ijms-26-08646"><title>4.8. Immunostaining Analysis</title><p>For immunocytochemistry, monolayers of CGF-released cells and BMSCs were prepared in parallel for each differentiation model. They were incubated overnight with antibodies against eNOS at concentrations of 1 &#956;g/mL and with the antibody against VEGFR-2 at a concentration of 0.2 &#956;g/mL, and Tubulin &#946;-III at a concentration of 10 &#956;g/mL. After 3 washes with PBS, the monolayers were incubated for 1 h with a biotinylated anti-mouse IgG antibody (AB_228305 Thermo Fisher, Rodano, Italy) for eNOS and Tubulin &#946;-III or an anti-rabbit IgG antibody (AP132B Millipore) for VEGFR-2. This was followed by a further 1 h incubation with peroxidase-conjugated streptavidin (E2886 Sigma-Aldrich, Merk Life Science S.r.l., Milan, Italy). The monolayers were then incubated with diaminobenzidine (91-95-2 Sigma-Aldrich) for five minutes, washed, and images were acquired at magnifications of 4&#215;, 10&#215;, and 20&#215; using an Invitrogen&#8482; EVOS XL Core imaging system.</p></sec><sec id="sec4dot9-ijms-26-08646"><title>4.9. Isolation of RNA and Real-Time PCR Analysis</title><p>Total RNA was extracted from CGF-released cells or BMSCs seeded in 12-well cultured plates at a density of 1 &#215; 10<sup>4</sup> for each specific differentiation time. Only RNA without DNA contamination was used for the subsequent preparation of cDNA synthesis. The reverse transcription reaction (20 &#956;L) was carried out using 1 &#956;g of total RNA, 25 ng of random hexamers, and the MultiScribe<sup>&#174;</sup> Reverse Transcriptase (Applied Biosystem, Monza, Italy), according to the manufacturer&#8217;s protocols. Quantitative gene expression analysis was performed in a CFX Connect Real-time System (BioRad, Segrate, Italy) using SsoAdvanced Universal SYBR Green Supermix (BioRad). The quantifications were performed using the &#8710;&#8710;CT method, and the Glyceraldehyde 3-phosphate dehydrogenase (<italic toggle="yes">Gapdh</italic>) was used as an internal control for normalization [<xref rid="B12-ijms-26-08646" ref-type="bibr">12</xref>]. The specificity of the PCR products was confirmed by the melting curve analysis. The sequences of primers used in real-time PCR are reported in <xref rid="ijms-26-08646-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec4dot10-ijms-26-08646"><title>4.10. Western Blot Analysis</title><p>CPCs and BMSCs were seeded under each experimental condition to obtain cellular protein extracts. An equal amount of proteins was loaded onto a 15% polyacrylamide gel, and Western blot was carried out as reported in [<xref rid="B37-ijms-26-08646" ref-type="bibr">37</xref>]. Separated proteins were then transferred electrophoretically onto a nitrocellulose membrane (Pall, East Hills, NY, USA). Equal protein loading was confirmed by Ponceau S staining. The filter was blocked with 5% (w/v) non-fat dried milk in buffered saline. Blots were incubated with primary antibodies directed against PPAR&#947; (sc-7273, Santa Cruz, CA, USA), adiponectin (AB3269P, Millipore), FASN (BD-610963, BD bioscience, Milan, Italy), CD105 (sc-18893), Tubulin &#946;-III (sc-80005) or or &#946;-actin (sc-47778), with the latter used as a control. The membranes were incubated with HRP-conjugated secondary antibodies, anti-mouse (A90-116P) and anti-rabbit (A120-101P), for 1 h at room temperature, and immunoreactive bands were identified employing an improved chemiluminescence detection kit (#1705061, Amersham International, Corston Bath, UK). Densitometric analysis was carried out on the Western blots using the ChemiDoc MP Image System (BioRad, Segrate, MI, Italy).</p></sec><sec id="sec4dot11-ijms-26-08646"><title>4.11. Morphometric Analysis</title><p>For morphological assessment, images of cells from each experimental condition were analyzed using ImageJ software (version 1.54f). Cell circularity was calculated using the formula 4&#960;(area/perimeter<sup>2</sup>), roundness was defined as (4 &#215; area)/(&#960; &#215; major axis<sup>2</sup>), and the perimeter-to-area ratio was also considered. Solidity was calculated as the ratio between the cell area and the area of its convex hull. In addition to these parameters, a PCA was performed using a broader set of morphometric descriptors extracted with ImageJ. For each experimental group, between 60 and 80 individual cells were analyzed.</p></sec><sec id="sec4dot12-ijms-26-08646"><title>4.12. Statistical Analysis</title><p>All experiments were independently repeated at least three times. Data are presented as mean values &#177; SD. Statistical evaluations were performed using GraphPad Prism version 9.5 (GraphPad Software, Boston, MA, USA). Differences between groups were assessed using the Student&#8217;s t-test and one-way analysis of variance (ANOVA) followed by the Bonferroni/Dunn post hoc test. Principal component analysis (PCA) was performed on morphometric parameters obtained using ImageJ software. Prior to analysis, variables were normalized to account for differences in measurement scales. PCA was conducted using GraphPad Prism version 9.1 (GraphPad Software, San Diego, CA, USA), and the first two principal components (PC1 and PC2) were extracted to visualize potential clustering among samples. Separate PCA analyses were carried out for different experimental datasets. In <xref rid="ijms-26-08646-f002" ref-type="fig">Figure 2</xref>, PC1 and PC2 explained 40.52% and 20.21% of the variance, respectively. In <xref rid="ijms-26-08646-f003" ref-type="fig">Figure 3</xref>, PC1 and PC2 explained 43.56% and 20.08%, respectively. In <xref rid="ijms-26-08646-f006" ref-type="fig">Figure 6</xref>, PC1 and PC2 explained 40.64% and 16.43%, respectively. In <xref rid="ijms-26-08646-f007" ref-type="fig">Figure 7</xref>, PC1 and PC2 explained 30.38% and 17.40%, respectively.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to Silfradent Srl at Forl&#236; (Italy) for providing Medifuge MF200 to obtain CGF.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, E.S. and L.G.; methodology, E.S., N.C. and L.G.; validation, E.S., N.C. and L.G.; formal analysis, M.A.D.S., F.S. and F.D.; investigation, E.S., N.C., F.S. and L.G.; project administration, L.S., M.A.C., C.D. and A.P.; data curation, E.S., N.C., F.S., B.D.C.S. and L.G.; writing&#8212;original draft preparation, E.S. and L.G.; writing&#8212;review and editing F.D., N.C., B.D.C.S. and M.A.C.; supervision, L.S. and M.A.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The national law 261/2007 authorizes the preparation of blood derivatives in a dental office. All samples were obtained in Dr. Palermo&#8217;s dental office from volunteers. Dr Palermo obtained the necessary authorizations for medical and surgical practice. However, we obtained the mandatory informed consent from all the donors included in the study according to the Declaration of Helsinki.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-26-08646"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorentino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roffi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Filardo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marcacci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kon</surname><given-names>E.</given-names></name></person-group><article-title>European Definitions, Current Use, and EMA Stance of Platelet-Rich Plasma in Sports Medicine</article-title><source>J. Knee Surg.</source><year>2015</year><volume>28</volume><fpage>51</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1396016</pub-id><pub-id pub-id-type="pmid">25419835</pub-id></element-citation></ref><ref id="B2-ijms-26-08646"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.Y.W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name></person-group><article-title>Characterisation of multipotent stem cells from human peripheral blood using an improved protocol</article-title><source>J. Orthop. Transl.</source><year>2019</year><volume>19</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jot.2019.02.003</pub-id><pub-id pub-id-type="pmcid">PMC6896479</pub-id><pub-id pub-id-type="pmid">31844610</pub-id></element-citation></ref><ref id="B3-ijms-26-08646"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cesselli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beltrami</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Rigo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bergamin</surname><given-names>N.</given-names></name><name name-style="western"><surname>D&#8217;Aurizio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Verardo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Piazza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klaric</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fanin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Toffoletto</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Multipotent progenitor cells are present in human peripheral blood</article-title><source>Circ. Res.</source><year>2009</year><volume>104</volume><fpage>1225</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.195859</pub-id><pub-id pub-id-type="pmid">19390058</pub-id></element-citation></ref><ref id="B4-ijms-26-08646"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuwana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kodama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yasuoka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>Y.</given-names></name></person-group><article-title>Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation</article-title><source>J. Leucoc. Biol.</source><year>2003</year><volume>74</volume><fpage>833</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1189/jlb.0403170</pub-id><pub-id pub-id-type="pmid">12960274</pub-id></element-citation></ref><ref id="B5-ijms-26-08646"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Glesne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huberman</surname><given-names>E.</given-names></name></person-group><article-title>A human peripheral blood monocyte-derived subset acts as pluripotent stem cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>2426</fpage><lpage>2431</lpage><pub-id pub-id-type="doi">10.1073/pnas.0536882100</pub-id><pub-id pub-id-type="pmid">12606720</pub-id><pub-id pub-id-type="pmcid">PMC151357</pub-id></element-citation></ref><ref id="B6-ijms-26-08646"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Liddo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bertalot</surname><given-names>T.</given-names></name><name name-style="western"><surname>Borean</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pirola</surname><given-names>I.</given-names></name><name name-style="western"><surname>Argentoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schrenk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cenzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Capelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Conconi</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Parnigotto</surname><given-names>P.P.</given-names></name></person-group><article-title>Leucocyte and Platelet-rich Fibrin: A carrier of autologous multipotent cells for regenerative medicine</article-title><source>J. Cell. Mol. Med.</source><year>2018</year><volume>22</volume><fpage>1840</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13468</pub-id><pub-id pub-id-type="pmid">29314633</pub-id><pub-id pub-id-type="pmcid">PMC5824368</pub-id></element-citation></ref><ref id="B7-ijms-26-08646"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ntege</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Sunami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y.</given-names></name></person-group><article-title>Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature</article-title><source>Regen. Ther.</source><year>2022</year><volume>21</volume><fpage>527</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1016/j.reth.2022.10.005</pub-id><pub-id pub-id-type="pmid">36382136</pub-id><pub-id pub-id-type="pmcid">PMC9637724</pub-id></element-citation></ref><ref id="B8-ijms-26-08646"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Platelet concentrates in diabetic foot ulcers: A comparative review of PRP, PRF, and CGF with case insights</article-title><source>Regen. Ther.</source><year>2025</year><volume>28</volume><fpage>625</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.reth.2025.02.005</pub-id><pub-id pub-id-type="pmid">40166040</pub-id><pub-id pub-id-type="pmcid">PMC11955794</pub-id></element-citation></ref><ref id="B9-ijms-26-08646"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.B.</given-names></name></person-group><article-title>Effect of neural-induced mesenchymal stem cells and platelet-rich plasma on facial nerve regeneration in an acute nerve injury model</article-title><source>Laryngoscope</source><year>2010</year><volume>120</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1002/lary.20860</pub-id><pub-id pub-id-type="pmid">20422684</pub-id></element-citation></ref><ref id="B10-ijms-26-08646"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Erg&#252;n</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kotan</surname><given-names>D.</given-names></name><name name-style="western"><surname>G&#252;rsoy</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Parman</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zengin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nurten</surname><given-names>A.</given-names></name></person-group><article-title>Effects of insulin-like growth factor-I and platelet-rich plasma on sciatic nerve crush injury in a rat model</article-title><source>J. Neurosurg.</source><year>2011</year><volume>114</volume><fpage>522</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.3171/2010.9.JNS091928</pub-id><pub-id pub-id-type="pmid">21029038</pub-id></element-citation></ref><ref id="B11-ijms-26-08646"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodella</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Favero</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boninsegna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Buffoli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Labanca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scar&#236;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Batani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rezzani</surname><given-names>R.</given-names></name></person-group><article-title>Growth factors, CD34 positive cells, and fibrin network analysis in concentrated growth factors fraction</article-title><source>Microsc. Res. Tech.</source><year>2011</year><volume>74</volume><fpage>772</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1002/jemt.20968</pub-id><pub-id pub-id-type="pmid">21780251</pub-id></element-citation></ref><ref id="B12-ijms-26-08646"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanca</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calabriso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Giannotti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Stanca</surname><given-names>B.D.C.</given-names></name><name name-style="western"><surname>Carluccio</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>De Benedetto</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Demitri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Analysis of CGF Biomolecules, Structure, and Cell Population: Characterization of the Stemness Features of CGF Cells and Osteogenic Potential</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>8867</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22168867</pub-id><pub-id pub-id-type="pmid">34445573</pub-id><pub-id pub-id-type="pmcid">PMC8396261</pub-id></element-citation></ref><ref id="B13-ijms-26-08646"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calabriso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stanca</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rochira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Giannotti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Chiara Stanca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Massaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scoditti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Demitri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Angiogenic Properties of Concentrated Growth Factors (CGFs): The Role of Soluble Factors and Cellular Components</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>635</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13050635</pub-id><pub-id pub-id-type="pmid">33946931</pub-id><pub-id pub-id-type="pmcid">PMC8146902</pub-id></element-citation></ref><ref id="B14-ijms-26-08646"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#228;r</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Diaz-Romero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kohl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zumstein</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nesic</surname><given-names>D.</given-names></name></person-group><article-title>Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro</article-title><source>Clin. Orthop. Relat. Res.</source><year>2015</year><volume>473</volume><fpage>1635</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1007/s11999-015-4192-2</pub-id><pub-id pub-id-type="pmid">25690170</pub-id><pub-id pub-id-type="pmcid">PMC4385378</pub-id></element-citation></ref><ref id="B15-ijms-26-08646"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isobe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Watanebe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawase</surname><given-names>T.</given-names></name></person-group><article-title>Mechanical and degradation properties of advanced platelet-rich fibrin (APRF), concentrated growth factors (CGF), and platelet-poor plasma-derived fibrin (PPTF)</article-title><source>Int. J. Implant Dent.</source><year>2017</year><volume>3</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s40729-017-0081-7</pub-id><pub-id pub-id-type="pmid">28466249</pub-id><pub-id pub-id-type="pmcid">PMC5413460</pub-id></element-citation></ref><ref id="B16-ijms-26-08646"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Quantification of growth factors in advanced platelet-rich fibrin and concentrated growth factors and their clinical efficacy as adjunctive to the GTR procedure in periodontal intrabony defects</article-title><source>J. Periodontol.</source><year>2020</year><volume>91</volume><fpage>462</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1002/JPER.19-0290</pub-id><pub-id pub-id-type="pmid">31471902</pub-id></element-citation></ref><ref id="B17-ijms-26-08646"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>J.</given-names></name><name name-style="western"><surname>Theunissen</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G.</given-names></name><name name-style="western"><surname>van Oosten</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Barrandon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wray</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>I.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.</given-names></name></person-group><article-title>Nanog is the gateway to the pluripotent ground state</article-title><source>Cell</source><year>2009</year><volume>138</volume><fpage>722</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.07.039</pub-id><pub-id pub-id-type="pmid">19703398</pub-id><pub-id pub-id-type="pmcid">PMC3437554</pub-id></element-citation></ref><ref id="B18-ijms-26-08646"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Concentrated growth factor promotes Schwann cell migration partly through the integrin &#946;1-mediated activation of the focal adhesion kinase pathway</article-title><source>Int. J. Mol. Med.</source><year>2016</year><volume>37</volume><fpage>1363</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2016.2520</pub-id><pub-id pub-id-type="pmid">26986804</pub-id></element-citation></ref><ref id="B19-ijms-26-08646"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name></person-group><article-title>Study on the Application of Concentrated Growth Factor Combined With Adipose Transplantation in Repairing Depressed Deformities of Soft Tissue in the Face</article-title><source>Ann. Plast. Surg.</source><year>2023</year><volume>91</volume><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1097/SAP.0000000000003666</pub-id><pub-id pub-id-type="pmid">37624903</pub-id></element-citation></ref><ref id="B20-ijms-26-08646"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Q.F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.Q.</given-names></name></person-group><article-title>An in vitro study of the angiogenic effects of concentrate growth factor on human umbilical vein endothelial cells</article-title><source>West China J. Stom.</source><year>2018</year><volume>36</volume><fpage>247</fpage><lpage>251</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.7518/hxkq.2018.03.003</pub-id><pub-id pub-id-type="pmcid">PMC7030300</pub-id><pub-id pub-id-type="pmid">29984922</pub-id></element-citation></ref><ref id="B21-ijms-26-08646"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannotti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Chiara Stanca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Spedicato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Demitri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calabriso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Carluccio</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Siculella</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Progress in Regenerative Medicine: Exploring Autologous Platelet Concentrates and Their Clinical Applications</article-title><source>Genes</source><year>2023</year><volume>14</volume><elocation-id>1669</elocation-id><pub-id pub-id-type="doi">10.3390/genes14091669</pub-id><pub-id pub-id-type="pmid">37761809</pub-id><pub-id pub-id-type="pmcid">PMC10530962</pub-id></element-citation></ref><ref id="B22-ijms-26-08646"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanca</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giannotti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Chiara Stanca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Siculella</surname><given-names>L.</given-names></name></person-group><article-title>Platelet Derivatives in Oncology: Dual Role in Tissue Regeneration and Tumor Progression</article-title><source>Med. Regen. Med.</source><year>2025</year><volume>3</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.55828/mrm-31-01</pub-id></element-citation></ref><ref id="B23-ijms-26-08646"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name></person-group><article-title>Evaluation of the safety and efficacy of concentrated growth factors for hair growth promotion in androgenetic alopecia patients: A retrospective single-centre, single-arm study</article-title><source>J. Cosmet. Dermatol.</source><year>2024</year><volume>23</volume><fpage>4051</fpage><lpage>4056</lpage><pub-id pub-id-type="doi">10.1111/jocd.16519</pub-id><pub-id pub-id-type="pmid">39169643</pub-id><pub-id pub-id-type="pmcid">PMC11626311</pub-id></element-citation></ref><ref id="B24-ijms-26-08646"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Novel Applications of Concentrated Growth Factors in Facial Rejuvenation and Plastic Surgery</article-title><source>Facial Plast. Surg.</source><year>2024</year><volume>40</volume><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1055/a-1987-3459</pub-id><pub-id pub-id-type="pmid">36423628</pub-id></element-citation></ref><ref id="B25-ijms-26-08646"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talaat</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Ghoneim</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Salah</surname><given-names>O.</given-names></name><name name-style="western"><surname>Adlly</surname><given-names>O.A.</given-names></name></person-group><article-title>Autologous bone marrow concentrates and concentrated growth factors accelerate bone regeneration after enucleation of mandibular pathologic lesions</article-title><source>J. Craniofac. Surg.</source><year>2018</year><volume>29</volume><fpage>992</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1097/SCS.0000000000004371</pub-id><pub-id pub-id-type="pmid">29481504</pub-id></element-citation></ref><ref id="B26-ijms-26-08646"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palermo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giannotti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Chiara Stanca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ferrante</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gnoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Calabriso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Demitri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Batani</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Use of CGF in Oral and Implant Surgery: From Laboratory Evidence to Clinical Evaluation</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>15164</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232315164</pub-id><pub-id pub-id-type="pmid">36499489</pub-id><pub-id pub-id-type="pmcid">PMC9736623</pub-id></element-citation></ref><ref id="B27-ijms-26-08646"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>B.</given-names></name></person-group><article-title>Efficacy of concentrated growth factor combined with coronally advanced flap in the treatment of gingival recession: A systematic review and meta-analysis</article-title><source>BMC Oral Health</source><year>2025</year><volume>25</volume><elocation-id>508</elocation-id><pub-id pub-id-type="doi">10.1186/s12903-025-05890-x</pub-id><pub-id pub-id-type="pmid">40205617</pub-id><pub-id pub-id-type="pmcid">PMC11984236</pub-id></element-citation></ref><ref id="B28-ijms-26-08646"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xv</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name></person-group><article-title>Concentrated growth factor (CGF): The newest platelet concentrate and its application in nasal hyaluronic acid injection complications</article-title><source>Aesthet. Plast. Surg.</source><year>2023</year><volume>47</volume><fpage>1785</fpage><lpage>1793</lpage><pub-id pub-id-type="doi">10.1007/s00266-023-03289-z</pub-id><pub-id pub-id-type="pmid">36849662</pub-id></element-citation></ref><ref id="B29-ijms-26-08646"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name></person-group><article-title>Autologous Bioactive Compound Concentrated Growth Factor Ameliorates Fistula Healing of Anal Fistula in a Pig Model and Promotes Proliferation and Migration of Human Skin Fibroblasts via Regulating the MEK/ERK Pathway</article-title><source>Oxid. Med. Cell. Longev.</source><year>2022</year><volume>2022</volume><fpage>7660118</fpage><pub-id pub-id-type="doi">10.1155/2022/7660118</pub-id><pub-id pub-id-type="pmid">36281422</pub-id><pub-id pub-id-type="pmcid">PMC9587676</pub-id></element-citation></ref><ref id="B30-ijms-26-08646"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Concentrated Growth Factor Enhanced Fat Graft Survival: A Comparative Study</article-title><source>Dermatol. Surg.</source><year>2018</year><volume>44</volume><fpage>976</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1097/DSS.0000000000001337</pub-id><pub-id pub-id-type="pmid">29894435</pub-id></element-citation></ref><ref id="B31-ijms-26-08646"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ungefroren</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hyder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>M.</given-names></name><name name-style="western"><surname>El-Sayed</surname><given-names>K.M.F.</given-names></name><name name-style="western"><surname>Grage-Griebenow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nussler</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>F&#228;ndrich</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name></person-group><article-title>Peripheral Blood Monocytes as Adult Stem Cells: Molecular Characterization and Improvements in Culture Conditions to Enhance Stem Cell Features and Proliferative Potential</article-title><source>Stem Cells Int.</source><year>2016</year><volume>2016</volume><fpage>7132751</fpage><pub-id pub-id-type="doi">10.1155/2016/7132751</pub-id><pub-id pub-id-type="pmid">26798361</pub-id><pub-id pub-id-type="pmcid">PMC4699085</pub-id></element-citation></ref><ref id="B32-ijms-26-08646"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bernabeu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smadja</surname><given-names>D.M.</given-names></name></person-group><article-title>Endoglin as an Adhesion Molecule in Mature and Progenitor Endothelial Cells: A Function Beyond TGF-&#946;</article-title><source>Front. Med.</source><year>2019</year><volume>6</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2019.00010</pub-id><pub-id pub-id-type="pmid">30761306</pub-id><pub-id pub-id-type="pmcid">PMC6363663</pub-id></element-citation></ref><ref id="B33-ijms-26-08646"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name></person-group><article-title>Efficacy and mechanisms of concentrated growth factor on facial nerve rehabilitation in a rabbit model</article-title><source>Biomater Sci.</source><year>2025</year><volume>13</volume><fpage>1059</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1039/D4BM01454E</pub-id><pub-id pub-id-type="pmid">39831451</pub-id></element-citation></ref><ref id="B34-ijms-26-08646"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannotti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Chiara Stanca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Spedicato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Demitri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calabriso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Carluccio</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferrante</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Hydroxyapatite-Silicon Scaffold Promotes Osteogenic Differentiation of CGF Primary Cells</article-title><source>Biology</source><year>2023</year><volume>12</volume><elocation-id>528</elocation-id><pub-id pub-id-type="doi">10.3390/biology12040528</pub-id><pub-id pub-id-type="pmid">37106729</pub-id><pub-id pub-id-type="pmcid">PMC10135480</pub-id></element-citation></ref><ref id="B35-ijms-26-08646"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bertalot</surname><given-names>T.</given-names></name><name name-style="western"><surname>Piccione</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gasparella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parnigotto</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Di Liddo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Conconi</surname><given-names>M.T.</given-names></name></person-group><article-title>Growth and Differentiation of Circulating Stem Cells After Extensive Ex Vivo Expansion</article-title><source>Tissue Eng. Regen. Med.</source><year>2021</year><volume>18</volume><fpage>411</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1007/s13770-021-00330-7</pub-id><pub-id pub-id-type="pmid">33625723</pub-id><pub-id pub-id-type="pmcid">PMC8169750</pub-id></element-citation></ref><ref id="B36-ijms-26-08646"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Halim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Song</surname><given-names>A.G.</given-names></name></person-group><article-title>Mesenchymal Stem Cell Migration and Tissue Repair</article-title><source>Cells</source><year>2019</year><volume>8</volume><elocation-id>784</elocation-id><pub-id pub-id-type="doi">10.3390/cells8080784</pub-id><pub-id pub-id-type="pmid">31357692</pub-id><pub-id pub-id-type="pmcid">PMC6721499</pub-id></element-citation></ref><ref id="B37-ijms-26-08646"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanca</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spedicato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Giudetti</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Giannotti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Chiara Stanca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Damiano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Siculella</surname><given-names>L.</given-names></name></person-group><article-title>EPA and DHA Enhance CACT Promoter Activity by GABP/NRF2</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>9095</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25169095</pub-id><pub-id pub-id-type="pmid">39201781</pub-id><pub-id pub-id-type="pmcid">PMC11354350</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-26-08646-f001" orientation="portrait"><label>Figure 1</label><caption><p>Morphological and immunophenotypic profile of CPCs. (<bold>A</bold>) The micrographs showed CPCs released by CGF pieces after 15 days and 21 days from cutting. They are representative of three independent experiments. (<bold>B</bold>) Real-time PCR analysis of stem cell surface and pluripotent markers in CPCs compared with BMSCs. <italic toggle="yes">Gapdh</italic> was used as a housekeeping gene. The results are expressed as means &#177; SD of triplicate measurements from four independent experiments. * <italic toggle="yes">p</italic> &#8805; 0.05, ** <italic toggle="yes">p</italic> &#8805; 0.01 relative to BMSCs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08646-g001.jpg"/></fig><fig position="float" id="ijms-26-08646-f002" orientation="portrait"><label>Figure 2</label><caption><p>Adipogenic differentiation of CPCs. (<bold>A</bold>) Oil Red O (ORO) staining in CPCs grown in basal medium (CTR) or adipogenic medium within 2 weeks. Images are representative of three independent experiments. (<bold>B</bold>) ORO staining intensity was quantified using image analysis ImageJ software (1.54v). (<bold>C</bold>) Morphometric analysis of roundness and the ratio between perimeter and area of CPCs grown in basal medium (CTR) or in adipogenic medium at 14 days, analyzed using ImageJ software (version 1.54f). (<bold>D</bold>) Real-time PCR analysis of stemness and adipocyte-specific gene expression. Total RNA was extracted from CPCs grown in basal medium (CTR) or in adipogenic medium at days 7 and 14. The mRNA expression of stemness and adipocyte-specific genes was analyzed by real-time PCR and normalized with <italic toggle="yes">Gapdh</italic>. (<bold>E</bold>) Protein expression levels in total protein extracts of CPCs grown in basal medium (CTR) or adipogenic medium at days 7 and 14. Western blots were probed with specific primary antibodies against FASN, adiponectin, and PPAR&#947;. Blots of total extracts were normalized vs. &#946;-actin. Each bar represents the mean &#177; standard deviation (SD) (<italic toggle="yes">n</italic> = 3). * <italic toggle="yes">p</italic> &#8805; 0.05, ** <italic toggle="yes">p</italic> &#8805; 0.01, **** <italic toggle="yes">p</italic> &lt; 0.0001 relative to CTR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08646-g002.jpg"/></fig><fig position="float" id="ijms-26-08646-f003" orientation="portrait"><label>Figure 3</label><caption><p>Adipogenic differentiation of BMSCs. (<bold>A</bold>) ORO staining in BMSC growing in basal medium (CTR) or adipogenic medium within 2 weeks. (<bold>B</bold>) ORO staining intensity was quantified using image analysis ImageJ software (1.54v). (<bold>C</bold>) Morphometric analysis of roundness and the ratio between perimeter and area of BMSCs grown in basal medium (CTR) or in adipogenic medium at day 14, analyzed using ImageJ software (version 1.54f). (<bold>D</bold>) Real-time PCR analysis of adipocyte-specific gene expression. Total RNA was extracted from BMSCs grown in basal medium (CTR) or in adipogenic medium at day 14. The mRNA expression of stemness and adipocyte-specific genes was analyzed by real-time PCR and normalized with <italic toggle="yes">Gapdh</italic>. Each bar represents the mean &#177; SD (<italic toggle="yes">n</italic> = 3). ** <italic toggle="yes">p</italic> &#8805; 0.01, **** <italic toggle="yes">p</italic> &lt; 0.0001 relative to CTR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08646-g003.jpg"/></fig><fig position="float" id="ijms-26-08646-f004" orientation="portrait"><label>Figure 4</label><caption><p>Endothelial differentiation of CPCs. (<bold>A</bold>) Immunostaining analysis was performed for eNOS and VEGFR-2. RNA was extracted from CPCs grown in basal medium (CTR) or in endothelial medium at days 7 and 14. The mRNA expression of endothelial-specific genes (<bold>B</bold>). and stemness genes (<bold>C</bold>) was analyzed by real-time PCR and normalized with <italic toggle="yes">Gapdh</italic>. Each bar represents the mean &#177; SD (<italic toggle="yes">n</italic> = 3). * <italic toggle="yes">p</italic> &#8805; 0.05, ** <italic toggle="yes">p</italic> &#8805; 0.01 relative to CTR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08646-g004.jpg"/></fig><fig position="float" id="ijms-26-08646-f005" orientation="portrait"><label>Figure 5</label><caption><p>Endothelial differentiation of BMSCs. (<bold>A</bold>) Immunostaining analysis was performed for eNOS and VEGFR-2. Images are representative of three replicates for each condition. (<bold>B</bold>) RNA was extracted from BMSCs grown in basal medium (CTR) or in endothelial medium at days 7 and 14, and the expression of endothelial cell markers (CD105, eNOS, VEGFR-2, and CD31) was analyzed by real-time PCR. <italic toggle="yes">Gapdh</italic> was used as housekeeping gene. Each bar represents the mean &#177; SD (<italic toggle="yes">n</italic> = 3). * <italic toggle="yes">p</italic> &#8805; 0.05 relative to CTR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08646-g005.jpg"/></fig><fig position="float" id="ijms-26-08646-f006" orientation="portrait"><label>Figure 6</label><caption><p>Neuronal differentiation of CPCs. (<bold>A</bold>) Immunohistochemical staining for TUBB3 shows positive labeling in CPCs cultured in neuronal differentiation medium Neu compared to CTR, scale bar 400 &#956;m. (<bold>B</bold>) Morphometric analysis of ratio between perimeter and area, solidity, and PCA. (<bold>C</bold>) RNA was extracted from CPCs, CTR, or in Neu. The mRNA expression of stemness and neuronal-specific genes mRNA abundance was analyzed by real-time PCR. <italic toggle="yes">Gapdh</italic> was used as a housekeeping gene for normalization. (<bold>D</bold>) Western blot and densitometric analysis of TUBB3 and CD105 protein in Neu and CTR cells. &#946;-actin was used as a loading control. Results are expressed as mean &#177; SD of triplicate measurements (<italic toggle="yes">n</italic> = 3) ** <italic toggle="yes">p</italic> &lt; 0.01, **** <italic toggle="yes">p</italic> &lt; 0.0001 relative to CTR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08646-g006.jpg"/></fig><fig position="float" id="ijms-26-08646-f007" orientation="portrait"><label>Figure 7</label><caption><p>Neuronal differentiation of BMSCs. (<bold>A</bold>) Immunohistochemical staining for TUBB3 shows positive labeling in BMSCs. Cultured in neuronal differentiation medium (Neu) compared to CTR, scale bar 400 &#956;m. (<bold>B</bold>) Morphometric analysis of the ratio between perimeter and area, solidity, and PCA. (<bold>C</bold>) Real-time PCR analysis reveals downregulation of hematopoietic (CD45) and mesenchymal (CD105) markers and upregulation of neuronal genes, including TUBB3, Nes, and NLF, in Neu cells. <italic toggle="yes">Gapdh</italic> was used as a housekeeping gene for normalization. (<bold>D</bold>) Western blot and densitometric analysis confirm increased TUBB3 protein expression in Neu cells compared to CTR, and (<bold>E</bold>) Western blot analysis shows reduced CD105 expression in Neu cells, indicating a loss of mesenchymal traits. &#946;-actin was used as a loading control. Results are expressed as mean &#177; SD of triplicate measurements from three independent experiments. **** <italic toggle="yes">p</italic> &lt; 0.0001 relative to control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08646-g007.jpg"/></fig><table-wrap position="float" id="ijms-26-08646-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08646-t001_Table 1</object-id><label>Table 1</label><caption><p>Oligonucleotides used for real-time PCR analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequences (5&#8242;-3&#8242;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Accession Number</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAPDH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: ATGGCCTTCCGTGTCCCCAC<break/>R: ACGCCTGCTTCACCACCTTC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_014364.5">NM_014364.5</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTPRC (CD45)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: ATGACCATGTATTTGTGGCTTA<break/>R: TGGGGGAAGGTGTTGGGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_080921.3">NM_080921.3</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endoglin (CD105)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: TGGGGGAAGGTGTTGGGC<break/>R: GCCAGCATTGTCTCACTTCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001278138.1">NM_001278138.1</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thy1 (CD90)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CCACTCTGGCCATTCCC<break/>R: GAGCAGGAGCAGCAGCAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006288.5">NM_006288.5</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: AGCTTACGATTTTGCACACC<break/>R: CGGATCTGCTGAACCTTGG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="BC015940.1">BC015940.1</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CAATGAGGCCACAACAAACA<break/>R: GTGACTGGACAGAAGAGTTT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M81104.1">M81104.1</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: TGATGCCCAGTTTGAGGTC<break/>R: ACGTCTTCAGTGGGGTTGTC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000442.5">NM_000442.5</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: ATGCAGCCTCATTTCCACC<break/>R: AGGCCTTGGATGGAAGAAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000072.3">NM_000072.3</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CTGCAACTTCTCCGAACCTC<break/>R:CCAGTAGCTGAGCAGGAACC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M86511.1">M86511.1</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oct3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: TATTCAGCCAAACGACCATC<break/>R: GCAGGAACAAATTCTCCAGG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_002701.5">NM_002701.5</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: AGATGCCTCACACGGAGAC<break/>R: TCTTCTGTTTCTTGACCGGG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_024865.2">NM_024865.2</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLIN2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: ATGGCAGGCGACATCTACTC<break/>R: AAGGGACCTACCAGCCAGTT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001122.4">NM_001122.4</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FASN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CCTGCGTGGCCTTTGAAAT<break/>R: CATGTCCGTGAACTGCTGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_004104">NM_004104</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FABP4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: GTGGAAGTGACGCCTTTCAT<break/>R: TACTGGGCCAGGAATTTGAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001442.3">NM_001442.3</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: AGTCTCACATCTGGTTGGGG<break/>R: CTCTCTGTGCCTCTGGTTCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001177800.1">NM_001177800.1</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEGFR-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: AGCGATGGCCTCTTCTGTAA<break/>R: ACACGACTCCATGTTGGTCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_002253.2">NM_002253.2</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">eNOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: ACCCTCACCGCTACAACATC<break/>R: GCTCATTCTCCAGGTGCTTC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000603.4">NM_000603.4</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurofilament</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CCAAGACCTCCTCAACGTGAAG<break/>R: ATGCTTCCCACGCTGGTGAAAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006158">NM_006158</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nestin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: GCGGGCTACTGAAAAGTTCC<break/>R: CTCCAGGCTGAGGGACATCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006617.2">NM_006617.2</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tubulin &#946;-III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: TCAGCGTCTACTACAACGAGGC<break/>R: GCCTGAAGAGATGTCCAAAGGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006086">NM_006086</ext-link></td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>